Fo Hcc, related to treatment, we have in the advanced setting, some data presented at Asco Gi 2018 recently: for example, cabozantinb in place of sorafenib, or immunotberapy after sora failure.
I agree with Dr Luis Rodrigo that early detection is the best approach however new drugs are entering the scene Lenvatinib has a better progress free survival and higher response rate than sorafenib and we are waiting the results of nivolumab versus sorafenib